BioPharma Credit leads new $315m loan to Sebela BioPharma Credit (BPCR), the LSE-listed specialist life sciences debt investor, is to act as lead investor and collateral agent for a US$315m term loan to Sebela Pharmaceuticals, a US privately-held commercial-stage speciality pharmaceutical company focused on gastrointestinal, dermatology and women’s healthcare. BioPharma Credit will provide $194m of the loan principal […]
Trust stalwart Regeneron cuts Praluent price Investment trust stalwart Regeneron Pharmaceuticals (NASDAQ: REGN) and its partner Sanofi yesterday announced a deal with Express Scripts, under which they will substantially lower the net price of Praluent in exchange for exclusive coverage on the US pharmacy benefit manager’s national formulary. The move deals a blow to rival Amgen, […]
IBT tops up Shire and Celgene in March SV Health-managed International Biotech Trust (IBT) recorded a 3.2% fall in NAV in March, slightly under-performing the Nasdaq Biotechnology Index, which was down by 2.9% in sterling terms. The manager reported that the main positive contributors of NAV in the month were Shire Pharmaceuticals, Nektar Therapeutics and […]
OrbiMed-managed trusts benefit from Alexion’s rise Shares in trust favourite Alexion Pharmaceuticals (Nasdaq: ALXN) put on 12% last week on the back of a strong financial first quarter with upgraded guidance and positive top-line results from a phase III study of ALXN1210, the company’s longer-acting follow-up to its blockbuster Soliris in the ultra-rate disease of […]
Prothena blow-up leaves Woodford Patient Capital reeling Neil Woodford’s controversial and high-profile investment in Prothena (NASDAQ:PRTA) and its development programme for AL Amyloidosis has failed, costing the Woodford Patient Capital Investment Trust (WPCT) an estimated £50m based on the average $40/share acquisition cost of its large shareholding. Prothena’s US-listed stock has fallen by 68% this […]
Biotech Growth sells Amgen, buys Regeneron and Alexion in March OrbiMed-managed Biotech Growth Trust (BIOG) sold a large proportion of its stake in Amgen last month, while increasing its holdings in Regeneron and Alexion, according to an analysis of its top holdings disclosed in its latest factsheet. The shareholding in Amgen, which accounted for just over 10% of […]
